Literature DB >> 2912547

Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells.

W K Yung1, R Lotan, P Lee, D Lotan, P A Steck.   

Abstract

The growth-inhibitory activity of beta-all-trans-retinoic acid (RA) was examined on seven cultured human gliomas and cells derived from one normal brain. Response in monolayer cultures was heterogenous: three cell lines were completely resistant whereas five cell lines were growth inhibited with 50% inhibitory dose ranging from greater than 10(-5) to 1 x 10(-8) M. Two glioma cell lines capable of forming colonies in soft agar exhibited dose-dependent sensitivity to RA-induced growth inhibition, whereas another cell line was not affected by RA under either growth condition. Cell cycle analysis of the glial-derived cells has shown that the RA-sensitive cells accumulated in the G0-G1 phase. The cell surface expression of epidermal growth factor (EGF) receptors displayed by the various cells was either slightly increased or not affected by RA. In addition, the affinity of binding was slightly decreased in some sensitive cells. The activity of EGF receptor as assessed by immunocomplex-kinase assays revealed a dose-dependent decrease in autophosphorylation activity that appeared to correlate with the growth inhibition. The decrease in phosphokinase activity represented a dose-dependent inhibition of phosphorylation on tyrosine residues on EGF receptor as well as several other substrates. Furthermore, the autophosphorylation of either RA-treated or untreated EGF receptors occurred on similar amino acid residues. These results demonstrate that RA exhibits a heterogeneous growth-inhibitory activity against human glioma cells and suggest that the effects of RA may be mediated, at least in part, by modulation of EGF receptor phosphotyrosine kinase activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912547

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Multi-agent cytostatic treatment of 'low-grade' gliomas.

Authors:  M E Linskey
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

2.  Paucity of retinoic acid receptor alpha (RAR alpha) nuclear immunostaining in gliomas and inability of retinoic acid to influence neural cell adhesion molecule (NCAM) expression.

Authors:  B K Kleinschmidt-DeMasters; E A Orr; E Savelieva; G C Owens; C A Kruse
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

3.  Fucoxanthin Activates Apoptosis via Inhibition of PI3K/Akt/mTOR Pathway and Suppresses Invasion and Migration by Restriction of p38-MMP-2/9 Pathway in Human Glioblastoma Cells.

Authors:  Yugang Liu; Jian Zheng; Yan Zhang; Zhaotao Wang; Yang Yang; Miaochun Bai; Yiwu Dai
Journal:  Neurochem Res       Date:  2016-07-09       Impact factor: 3.996

4.  Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme.

Authors:  V A Levin; P Giglio; V K Puduvalli; J Jochec; M D Groves; W K A Yung; K Hess
Journal:  J Neurooncol       Date:  2005-11-29       Impact factor: 4.130

5.  Treatment of recurrent malignant gliomas with 13-cis-retinoic acid naphthalene triazole.

Authors:  Pi-Feng Jia; Wei-Ting Gu; Wei-Feng Zhang; Feng Li
Journal:  Neurol Sci       Date:  2015-01-06       Impact factor: 3.307

6.  All-trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications.

Authors:  G L Defer; H Adle-Biassette; F Ricolfi; L Martin; F J Authier; C Chomienne; L Degos; J D Degos
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

7.  All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma.

Authors:  S Phuphanich; C Scott; A J Fischbach; C Langer; W K Yung
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

8.  Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas.

Authors:  Chuanbing Zang; Marlies Wächter; Hongyu Liu; Maximilian G Posch; Martin H Fenner; Christine Stadelmann; Andreas von Deimling; Kurt Possinger; Keith L Black; H Phillip Koeffler; Elena Elstner
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

9.  Changes in CA125 release and surface expression caused by drugs in uterine cervix adenocarcinoma cells.

Authors:  T Nakai; H Sakahara; K Endo; M Shirato; H Kobayashi; M Hosono; T Saga; M Sakamoto; J Konishi
Journal:  Ann Nucl Med       Date:  1993-08       Impact factor: 2.668

10.  13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme.

Authors:  Siew-Ju See; Victor A Levin; W-K Alfred Yung; Kenneth R Hess; Morris D Groves
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.